title: [Cutaneous lupus erythematosus and skin manifestations in systemic lupus erythematosus].
abstract: Skin manifestations are frequently observed in lupus erythematosus (LE) and are manifold. Nonspecific and specific symptoms can be differentiated with the latter belonging to the dermatologically well-characterized clinical entities of acute cutaneous, subacute cutaneous, chronic cutaneous as well as intermittent cutaneous LE. These forms are differentially related to systemic LE. Patient history and clinical examinations, laboratory and immunoserological findings as well as organ imaging results determine the time point as well as the intensity of therapy. Apart from cessation of smoking and alcohol consumption as well as stringent UV protection, topical therapy with corticosteroids or calcineurin inhibitors may suffice with limited forms of the disease. In many cases, however, systemic treatment with antimalarial drugs as a basic treatment is mandatory. Several immunosuppressive agents can alternatively be used in conjunction with systemic corticosteroids. Early and effective therapy is important to prevent irreversible scarring of the skin and to avoid internal organ damage.
authors.affiliation: Hautklinik, Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Deutschland. michael.sticherling@uk-erlangen.de
authors.forename: M
authors.initials: M
authors.lastname: Sticherling
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D000962:Antimalarials / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008178:Lupus Erythematosus, Cutaneous / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D000962:Antimalarials; D007166:Immunosuppressive Agents